IDEXX Laboratories Gestion
Gestion contrôle des critères 4/4
Le PDG IDEXX Laboratories est Jay Mazelsky, nommé en Jun2019, a un mandat de 5.42 ans. La rémunération annuelle totale est $ 11.52M, composée du salaire de 8.7% et des bonus 91.3%, y compris les actions et options de la société. détient directement 0.1% des actions de la société, d'une valeur de $ 34.21M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 5.4 ans et 7.7 ans.
Informations clés
Jay Mazelsky
Directeur général
US$11.5m
Rémunération totale
| Pourcentage du salaire du PDG | 8.7% |
| Durée du mandat du directeur général | 5.4yrs |
| Propriété du PDG | 0.1% |
| Durée moyenne d'occupation des postes de direction | 5.4yrs |
| Durée moyenne du mandat des membres du conseil d'administration | 7.7yrs |
Mises à jour récentes de la gestion
Recent updates
At US$420, Is It Time To Put IDEXX Laboratories, Inc. (NASDAQ:IDXX) On Your Watch List?
Nov 19
IDEXX Laboratories Q3: Weak End-Market Demand Continues
Nov 11Investors Appear Satisfied With IDEXX Laboratories, Inc.'s (NASDAQ:IDXX) Prospects
Oct 28Here's Why We Think IDEXX Laboratories (NASDAQ:IDXX) Is Well Worth Watching
Oct 15We Think IDEXX Laboratories (NASDAQ:IDXX) Can Manage Its Debt With Ease
Sep 18A Look At The Intrinsic Value Of IDEXX Laboratories, Inc. (NASDAQ:IDXX)
Sep 05What Is IDEXX Laboratories, Inc.'s (NASDAQ:IDXX) Share Price Doing?
Aug 20IDEXX Laboratories Q2: Headwinds From Low U.S. Clinical Visits
Aug 12A Look Into IDEXX Laboratories' (NASDAQ:IDXX) Impressive Returns On Capital
Jul 02Looking For Fast Growth In Healthcare? IDEXX Has You Covered
Jun 28Here's Why IDEXX Laboratories (NASDAQ:IDXX) Has Caught The Eye Of Investors
Jun 04Should You Think About Buying IDEXX Laboratories, Inc. (NASDAQ:IDXX) Now?
May 21IDEXX Laboratories, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
May 03What IDEXX Laboratories, Inc.'s (NASDAQ:IDXX) P/E Is Not Telling You
Apr 27IDEXX Laboratories (NASDAQ:IDXX) Has A Rock Solid Balance Sheet
Apr 11IDEXX: Strong Recurring Revenues From Consumables, Software But Overvalued (Rating Downgrade)
Apr 08Is It Too Late To Consider Buying IDEXX Laboratories, Inc. (NASDAQ:IDXX)?
Jan 30IDEXX Laboratories: Valuation Rerating Doesn't Seem Justified
Jan 16Here's Why IDEXX Laboratories (NASDAQ:IDXX) Has Caught The Eye Of Investors
Jan 15IDEXX Laboratories, Inc.'s (NASDAQ:IDXX) Shareholders Might Be Looking For Exit
Dec 31IDEXX Laboratories (NASDAQ:IDXX) Seems To Use Debt Rather Sparingly
Dec 15Why IDEXX Laboratories, Inc. (NASDAQ:IDXX) Could Be Worth Watching
Oct 26Here's Why We Think IDEXX Laboratories (NASDAQ:IDXX) Is Well Worth Watching
Oct 10Is IDEXX Laboratories (NASDAQ:IDXX) Using Too Much Debt?
Sep 07Is It Time To Consider Buying IDEXX Laboratories, Inc. (NASDAQ:IDXX)?
Jul 04These 4 Measures Indicate That IDEXX Laboratories (NASDAQ:IDXX) Is Using Debt Reasonably Well
May 31At US$484, Is IDEXX Laboratories, Inc. (NASDAQ:IDXX) Worth Looking At Closely?
Apr 05Here's Why IDEXX Laboratories (NASDAQ:IDXX) Can Manage Its Debt Responsibly
Feb 22Why IDEXX Laboratories, Inc. (NASDAQ:IDXX) Could Be Worth Watching
Jan 05Is IDEXX Laboratories (NASDAQ:IDXX) Using Too Much Debt?
Nov 24When Should You Buy IDEXX Laboratories, Inc. (NASDAQ:IDXX)?
Sep 20IDEXX Laboratories: Outstanding Business, But Valuation Is Key
Aug 15These 4 Measures Indicate That IDEXX Laboratories (NASDAQ:IDXX) Is Using Debt Reasonably Well
Aug 15IDEXX Laboratories Stock Is Very Expensive
Aug 08IDEXX Laboratories Non-GAAP EPS of $1.58 misses by $0.05, revenue of $860.55M misses by $1.57M
Aug 02Are IDEXX Laboratories, Inc. (NASDAQ:IDXX) Investors Paying Above The Intrinsic Value?
Jul 26Here's Why We Think IDEXX Laboratories (NASDAQ:IDXX) Might Deserve Your Attention Today
Jul 12Is It Time To Consider Buying IDEXX Laboratories, Inc. (NASDAQ:IDXX)?
Jun 16IDEXX Laboratories: Great Business, But Still Overvalued
May 25Analyse de la rémunération des PDG
| Date | Rémunération totale | Salaire | Bénéfices de l'entreprise |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$866m |
| Jun 30 2024 | n/a | n/a | US$846m |
| Mar 31 2024 | n/a | n/a | US$867m |
| Dec 31 2023 | US$12m | US$1m | US$845m |
| Sep 30 2023 | n/a | n/a | US$823m |
| Jun 30 2023 | n/a | n/a | US$791m |
| Mar 31 2023 | n/a | n/a | US$699m |
| Dec 31 2022 | US$10m | US$1m | US$679m |
| Sep 30 2022 | n/a | n/a | US$670m |
| Jun 30 2022 | n/a | n/a | US$664m |
| Mar 31 2022 | n/a | n/a | US$735m |
| Dec 31 2021 | US$9m | US$977k | US$745m |
| Sep 30 2021 | n/a | n/a | US$757m |
| Jun 30 2021 | n/a | n/a | US$728m |
| Mar 31 2021 | n/a | n/a | US$674m |
| Dec 31 2020 | US$7m | US$814k | US$582m |
| Sep 30 2020 | n/a | n/a | US$497m |
| Jun 30 2020 | n/a | n/a | US$460m |
| Mar 31 2020 | n/a | n/a | US$437m |
| Dec 31 2019 | US$7m | US$632k | US$428m |
| Sep 30 2019 | n/a | n/a | US$423m |
| Jun 30 2019 | n/a | n/a | US$407m |
| Mar 31 2019 | n/a | n/a | US$390m |
| Dec 31 2018 | US$3m | US$555k | US$377m |
| Sep 30 2018 | n/a | n/a | US$330m |
| Jun 30 2018 | n/a | n/a | US$307m |
| Mar 31 2018 | n/a | n/a | US$284m |
| Dec 31 2017 | US$2m | US$469k | US$263m |
Rémunération vs marché: La rémunération totale de Jay ($USD 11.52M ) est dans la moyenne des entreprises de taille similaire sur le marché US ($USD 12.73M ).
Rémunération et revenus: La rémunération de Jay a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.
PDG
Jay Mazelsky (63 yo)
5.4yrs
Titularisation
US$11,519,309
Compensation
Mr. Jonathan J. Mazelsky, also known as Jay, serves as Independent Director at DENTSPLY SIRONA Inc. since May 24, 2023. He has been President, Chief Executive Officer and Director at IDEXX Laboratories, In...
Équipe de direction
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| President | 5.4yrs | US$11.52m | 0.10% $ 34.2m | |
| CFO, Executive VP & Treasurer | 10.8yrs | US$3.85m | 0.060% $ 20.5m | |
| Executive VP and GM of Reference Laboratories & Information Technology | 4.8yrs | US$2.92m | 0.0086% $ 2.9m | |
| Senior Vice President of Global Operations | 7.2yrs | pas de données | pas de données | |
| Senior Vice President of Commercial Finance & Sales Operations | 9.8yrs | pas de données | pas de données | |
| Executive VP & CTO | 3.3yrs | pas de données | pas de données | |
| Senior VP & Chief Information Officer | 8.8yrs | pas de données | pas de données | |
| Executive VP | no data | US$1.88m | 0.0068% $ 2.3m | |
| Executive VP & Chief Human Resources Officer | 2.7yrs | pas de données | 0.00022% $ 75.4k | |
| Senior VP & Chief Revenue Officer | no data | pas de données | 0.0084% $ 2.9m | |
| Executive VP and GM of Point of Care Diagnostics & Telemedicine | no data | pas de données | 0.013% $ 4.5m | |
| Senior Vice President of Research & Development | 4.8yrs | pas de données | pas de données |
5.4yrs
Durée moyenne de l'emploi
55yo
Âge moyen
Gestion expérimentée: L'équipe dirigeante de IDXX est chevronnée et expérimentée (5.4 années d'ancienneté moyenne).
Membres du conseil d'administration
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| President | 5.1yrs | US$11.52m | 0.10% $ 34.2m | |
| Independent Director | 12.3yrs | US$367.66k | 0.0074% $ 2.5m | |
| Independent Director | 10.7yrs | US$362.66k | 0.0031% $ 1.1m | |
| Independent Director | 9.3yrs | US$367.66k | 0.0021% $ 719.8k | |
| Independent Director | 7.3yrs | US$350.16k | 0.0024% $ 826.1k | |
| Independent Non-Executive Chairman | 8.1yrs | US$495.02k | 0.0096% $ 3.3m | |
| Independent Director | 11.3yrs | US$335.16k | 0.011% $ 3.8m | |
| Independent Director | 1.3yrs | US$258.89k | 0.00025% $ 85.7k | |
| Independent Director | 5.3yrs | US$342.66k | 0% $ 0 | |
| Independent Director | 4yrs | US$335.16k | 0.00095% $ 325.6k |
7.7yrs
Durée moyenne de l'emploi
62yo
Âge moyen
Conseil d'administration expérimenté: Les membres du conseil d'administration de IDXX sont considérés comme expérimentés (ancienneté moyenne 7.7 ans).